切换导航

MOG (35-55)

现货
Catalog No.
A8306
CNS髓磷脂的微量成分
组合的产品项目
规格价格库存 数量
1mg
¥ 980.00
现货
5mg
¥ 2,940.00
现货

电话: 021-55669583

邮箱: sales@apexbio.cn

全球经销商

Background

MOG (35-55) is a truncated peptide derived from the human Myelin Oligodendrocyte Glycoprotein (MOG). MOG, a member of the immunoglobulin superfamily, is expressed wildly in the central nervous system. In mouse and rat models for human multiple sclerosis, MOG is involved in inducing the experimental autoimmune encephalomyelitis. Humoral auto-immunity to the myelin oligodendrocyte glycoprotein (MOG) may be associated with the pathogenesis of multiple sclerosis (MS) [1].

MOG (35-55) is involved in inducing autoantibody production and relapsing-remitting neurological disease causing extensive plaque-like demyelination [2]. In HLA-DR2-transgenic mice, Myelin oligodendrocyte glycoprotein-35-55 peptide induced severe chronic experimental autoimmune encephalomyelitis [3].MOG35-55 was highly encephalitogenic and could induce strong T and B cell responses in rats [4]. In NOD/Lt mice (H-2g7) and C57BL/6 mice (H-2b), single injection of MOG35-55 in CFA could induce MS-like disease [4].

References:
[1]. De March A K, De Bouwerie M, Kolopp-Sarda M N, et al. Anti-myelin oligodendrocyte glycoprotein B-cell responses in multiple sclerosis[J]. Journal of neuroimmunology, 2003, 135(1): 117-125.
[2]. Slavin A, Ewing C, Liu J, et al. Induction of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein[J]. Autoimmunity, 1998, 28(2): 109-120.
[3]. Rich C, Link J M, Zamora A, et al. Myelin oligodendrocyte glycoprotein‐35–55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA‐DR2‐transgenic mice[J]. European journal of immunology, 2004, 34(5): 1251-1261.
[4]. Slavin A, Ewing C, Liu J, et al. Induction of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein[J]. Autoimmunity, 1998, 28(2): 109-120.

文献引用

1. Xu L, Zhang C, et al. "Rapamycin combined with MCC950 to treat multiple sclerosis in experimental autoimmune encephalomyelitis." J Cell Biochem. 2018 Oct 15. PMID:30320900

Chemical Properties

Physical AppearanceA solid
StorageDesiccate at -20°C
M.Wt2581.97
Cas No.149635-73-4
FormulaC118H177N35O29S
Solubility≥32.25mg/mL in H2O, ≥86 mg/mL in DMSO, <2.15 mg/mL in EtOH
Chemical Name(S)-2-((Z)-((2S,3R)-3-amino-1,2-dihydroxy-4-phenylbutylidene)amino)-4-methylpentanoic acid compound with 2,2,2-trifluoroacetic acid (1:1)
SDFDownload SDF
Canonical SMILESCC(C[C@@](/N=C(O)/[C@](O)([H])[C@@](N)([H])CC1=CC=CC=C1)([H])C(O)=O)C.FC(F)(F)C(O)=O
运输条件试用装:蓝冰运输。 其他可选规格:常温运输或根据您的要求用蓝冰运输。
一般建议为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。

试验操作

细胞实验 [1]:

细胞系

脑内皮细胞

制备方法

在无菌水中的溶解度为0.50 mg/mL。若配制更高浓度的溶液,一般步骤如下:请将试管置于37 °C加热10分钟和/或将其置于超声波浴中震荡一段时间。原液于-20 °C可放置数月。

反应条件

0 ~ 50 μg/mL;48小时

实验结果

MOG (35-55) 呈剂量依赖性地显著降低蛋白浓度。给予细胞MOG (35-55) (50 μg/mL) + CFA + PTX,蛋白浓度降至CON细胞水平的37.6%。在25 μg/mL或50 μg/mL的剂量下,MOG (35-55) 乳液显著增加NADPH氧化酶和MMP-9的活性(相对于CON细胞,分别高出44.1 ~ 48.5%和2倍)。

动物实验 [2]:

动物模型

C57BL/6小鼠

给药剂量

50、100或150 μg;皮下注射

实验结果

与注射了150 μg MOG (35-55)的小鼠相比,在50 μg和100 μg的剂量下,MOG (35-55)在MS样疾病发展过程中引起更明显的体重减轻。于治疗后第17天,50 μg MOG (35-55)组中的3/5小鼠出现濒死症状,而100 μg和150 μg剂量组中的4/5小鼠仍然存活。然而,在这3组小鼠中,均没有观察到临床症状和疾病进展。

注意事项

请于室内测试所有化合物的溶解度。虽然化合物的实际溶解度可能与其理论值略有不同,但仍处于实验系统误差的允许范围内。

References:

[1]. Seo JE, Hasan M, Rahaman KA, Kang MJ, Jung BH, Kwon OS. A leading role for NADPH oxidase in an in-vitro study of experimental autoimmune encephalomyelitis. Mol Immunol. 2016 Apr;72:19-27.

[2]. Slavin A, Ewing C, Liu J, et al. Induction of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein[J]. Autoimmunity, 1998, 28(2): 109-120.

质量控制

化学结构

MOG (35-55)

相关生物数据

MOG (35-55)